In accordance with applicable privacy legislation, the company Kedrion S.p.a., controller of the data acquired via this website, hereby informs the user that said website does not use profiling cookies to send advertising messages tuned to preferences expressed when browsing the internet. This website installs third party cookies. Continuing to browse, including by scrolling down and clicking on website elements, equates to consent.
For more information, also as regards the technical cookies used by the website and to refuse consent to the installation of individual cookies, please refer to the complete cookies disclosure.
You are now leaving Kedrion Corporate site. Medical information including licensed uses may be different outside of the EU countries.
NO
YES
HIGHLIGHTS
EVENTS
EIGHT, the global educational initiative on Hemophilia A and its treatment
Experts from all over the world attended the EIGHT 2018 Conference in Budapest, Hungary on 12-13 October
read moreEVENTS
Kedrion Biopharma participates in the Mother and Child Conference in Moscow
A 50 years of Anti-D dedicated programme presented at the main Russian congress of Gynecology and Obstetrics
read moreEVENTS
Kedrion Joins Annual PNS Conference on Neurology
The company took part in the event with a booth and a delegation of 40 int’l guests
read more-
CORPORATE - 12-10-2015
Kedrion supports Fondazione Paracelso's activities in Afghanistan
Kedrion confirms its commitment to broaden access to hemophilia treatments in developing Countries
read more -
CORPORATE - 29-09-2015
Kedrion Notes 2019 Tender Offer results
Kedrion has accepted for purchase Notes validly tendered for a total aggregate principal amount equal to €150,716,000
read more -
CORPORATE - 21-09-2015
Cash Tender Offer for Notes due 24 April 2019
Kedrion S.p.A. announced Cash Tender Offer for its €300,000,000 4.625 per cent. outstanding Notes due 24 April 2019
read more -
CORPORATE - 20-07-2015
KEDPlasma welcomes donors to its new Augsburg collection center
Plasma collected in Germany is essential to Kedrion Biopharma’s plasma-derived therapies
read more
Pages
For more information please contact: pressoffice@kedrion.com
Where 